BioNTech SE ( bee-ON-tek; or bye-ON-tek short for Biopharmaceutical New Technologies) is a German biotechnology company based in Mainz that develops and manufactures active immunotherapies for patient-specific approaches to the treatment of diseases. It develops pharmaceutical candidates based on messenger ribonucleic acid (mRNA) for use as individualized cancer immunotherapies, as vaccines against infectious diseases and as protein replacement therapies for rare diseases, and also engineered cell therapy, novel antibodies and small molecule immunomodulators as treatment options for cancer.
BioNTech est une société allemande de biotechnologie spécialisée dans le développement et la fabrication d'immunothérapies actives dans le traitement des maladies graves.
BioNTech (voluit: Biopharmaceutical New Technologies) is een biotechnologiebedrijf dat is gevestigd in Mainz.
BioNTech SE (en alemán: Biontech, pronunciado /biː'ɒntɛk/[1], formado del inglés Biopharmaceutical New Technologies) es una empresa de biotecnología alemana dedicada al desarrollo y fabricación de inmunoterapias activas para un enfoque específico del paciente en el tratamiento de enfermedades graves.
A BioNTech é uma empresa (laboratório de biotecnologia) alemã criada em 2008 por um casal de cientistas alemães de origem turca. Ele, Ugur Sahin, médico, pesquisador na área de câncer e imunologia e CEO da BioNTech. Ela, Özlem Türeci, médica, professora de imunoterapia personalizada e médica-diretora da BioNTech .
La BioNTech è un'azienda tedesca di biotecnologia e biofarmaceutica attiva nell'ambito della ricerca, sviluppo e commercializzazione di farmaci.
no matches found